Hepatitis a disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HPT003 MIFTS: 62	Hepatitis a Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a ¹² ⁷⁴ ⁴² ⁴³ ¹⁵ ⁷¹

Viral Hepatitis, Type a ¹²

Viral Hepatitis a ¹²

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Liver diseases Gastrointestinal diseases Immune diseases Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Certain infectious and parasitic diseases

Viral hepatitis

Acute hepatitis A

Hepatitis A with hepatic coma

Hepatitis A without hepatic coma

External Ids:

Disease Ontology ¹² DOID:12549

MeSH ⁴³ D006506

NCIt ⁴⁹ C3096

SNOMED-CT ⁶⁷ 40468003

ICD10 ³² B15.0 B15.9

UMLS ⁷¹ C0019159

Sources

Summaries for Hepatitis a

MedlinePlus : ⁴² Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis A, is caused by the hepatitis A virus (HAV). The disease spreads through contact with an infected person's stool. You can get it from Eating food made by an infected person who did not wash their hands after using the bathroom Drinking untreated water or eating food washed in untreated water Putting into your mouth a finger or object that came into contact with an infected person's stool Having close contact with an infected person, such as through sex or caring for someone who is ill Most people do not have any symptoms. If you do have symptoms, you may feel as if you have the flu. You may also have yellowish eyes and skin, called jaundice. A blood test will show if you have HAV. HAV usually gets better in a few weeks without treatment. However, some people can have symptoms for up to 6 months. Your doctor may suggest medicines to help relieve your symptoms. The hepatitis A vaccine can prevent HAV. Good hygiene can also help. Wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. International travelers should be careful about drinking tap water. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to acute liver failure and fatty liver disease, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Innate Immune System and PI3K-Akt signaling pathway. The drugs Emtricitabine and Neomycin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : ¹² A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : ⁷⁴ Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral... more...

Sources

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus	Hepatitis a
Hepatitis C	Viral Hepatitis
Hepatitis B	Hepatitis D
Autoimmune Hepatitis	Hepatitis E
Autoimmune Hepatitis Type 2	Autoimmune Hepatitis Type 1

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 858)

#	Related Disease	Score	Top Affiliating Genes
1	acute liver failure	32.6	GPT F2 ALB
2	fatty liver disease	31.9	TNF TLR4 INS GPT GGT1 ALB
3	hepatitis e	31.8	TNF TLR3 IFNG GPT GGT1 F2
4	cutaneous leishmaniasis	31.2	TNF TLR4 IL10 IFNG
5	hepatitis	31.1	TNF TICAM1 SEPSECS MAVS IKBKG IFNG
6	liver disease	31.1	TNF SEPSECS INS IFNA1 GPT GGT1
7	hepatitis d	31.0	IFNA1 GPT F2
8	acute kidney failure	30.9	HAVCR1 GPT F2 ALB
9	hepatic coma	30.9	GPT F2 ALB AFP
10	granulomatous hepatitis	30.8	TNF GPT ALB
11	acalculous cholecystitis	30.7	GPT F2 ALB
12	hepatic encephalopathy	30.6	TNF GPT F2 ALB AFP
13	poliomyelitis	30.6	TNF IL10 IFNG AFP
14	cholestasis	30.5	TNF GPT GGT1 F2 CYP3A4 ALB
15	acute kidney tubular necrosis	30.5	TNF HAVCR1 GGT1 ALB
16	alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity	30.5	INS IL10 IFNG
17	purpura	30.5	TNF IL10 IFNG F2
18	hepatorenal syndrome	30.5	HAVCR1 GPT F2 ALB AFP
19	diphtheria	30.5	TNF IFNG IFNA1 ALB
20	cholecystitis	30.5	TLR4 GPT F2 ALB
21	gastroenteritis	30.5	TNF IL10 IFNG IFNA1 ALB
22	syphilis	30.4	TNF IFNG GPT F2 ALB
23	tetanus	30.4	TNF IL10 IFNG ALB
24	viral hepatitis	30.3	TNF TLR4 TLR3 SEPSECS INS IL10
25	pancreatitis	30.3	TNF INS IL10 GGT1 ALB
26	liver cirrhosis	30.3	IFNA1 GPT GGT1 F2 CYP3A4 ALB
27	autoimmune hepatitis	30.3	TNF SEPSECS IL10 IFNA1 GPT GGT1
28	hyperthyroidism	30.3	TNF INS GPT ALB
29	drug-induced hepatitis	30.2	TNF SEPSECS GPT F2 ALB
30	alcohol use disorder	30.2	GPT GGT1 CYP3A4 ALB
31	thyroiditis	30.2	TNF INS IL10 IFNA1
32	autoimmune disease	30.2	TNF INS IL10 IFNG IFNA1 HAVCR2
33	chickenpox	30.1	TNF TLR3 IL10 IFNG IFNA1 ALB
34	alcoholic hepatitis	30.1	TNF TLR4 IL10 GPT GGT1 F2
35	pericardial effusion	30.1	GPT F2 ALB
36	mumps	30.1	TNF TLR3 IL10 IFNG IFNA1
37	neuritis	30.1	TNF IL10 IFNG
38	hyperuricemia	30.1	INS GPT GGT1 ALB
39	measles	30.1	TNF TLR4 TLR3 IFNG IFNA1
40	pharyngitis	30.1	TNF GPT ALB
41	meningoencephalitis	30.1	TNF TLR3 IL10 ALB
42	bilirubin metabolic disorder	30.1	GPT GGT1 F2 CYP3A4 ALB AFP
43	acute pancreatitis	30.1	TNF TLR4 INS IL10 GPT ALB
44	leptospirosis	30.1	TNF IL10 IFNG F2
45	japanese encephalitis	30.1	TNF TLR3 IFNA1
46	cryoglobulinemia	30.1	TNF IL10 IFNG IFNA1 GPT
47	eclampsia	30.0	TNF F2 ALB
48	infantile liver failure syndrome 1	30.0	GPT F2 ALB
49	typhoid fever	30.0	TNF TLR4 IFNG GPT GGT1 F2
50	newcastle disease	29.9	TNF TLR3 IFNA1

Graphical network of the top 20 diseases related to Hepatitis a:

Sources

Symptoms & Phenotypes for Hepatitis a

Symptoms:

¹²

• vomiting
• fatigue
• fever
• abdominal pain
• jaundice

• nausea
• loss of appetite
• joint pain
• clay-colored bowel movements

UMLS symptoms related to Hepatitis a:

fever, pruritus, nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis a:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.29	ALB F2 HAVCR2 IFNG IKBKG IL10
2	homeostasis/metabolism	MP:0005376	10.27	AFP ALB F2 GGT1 IFNG IKBKG
3	hematopoietic system	MP:0005397	10.26	F2 GGT1 HAVCR2 IFNG IKBKG IL10
4	immune system	MP:0005387	10.25	ALB F2 GGT1 HAVCR2 IFNG IKBKG
5	digestive/alimentary	MP:0005381	10.19	ALB F2 IFNG IKBKG IL10 INS
6	mortality/aging	MP:0010768	10.17	AFP ALB F2 GGT1 HAVCR2 IFNG
7	integument	MP:0010771	10.06	F2 GGT1 IFNG IKBKG IL10 INS
8	liver/biliary system	MP:0005370	10.02	AFP ALB IFNG IKBKG IL10 INS
9	muscle	MP:0005369	9.86	ALB IFNG IL10 INS MAVS TLR3
10	neoplasm	MP:0002006	9.81	AFP ALB IFNG IKBKG IL10 TICAM1
11	reproductive system	MP:0005389	9.65	AFP F2 GGT1 IFNG IKBKG IL10
12	respiratory system	MP:0005388	9.23	F2 IFNG IL10 MAVS TICAM1 TLR3

Sources

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 433)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Emtricitabine

Approved, Investigational

Phase 4

143491-57-0

60877

Neomycin

Approved, Vet_approved

Phase 4

1404-04-2

8378

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Ezetimibe

Approved

Phase 4

163222-33-1

150311

glycyrrhizin

Approved, Experimental

Phase 4

1405-86-3

3495

Rifampicin

Approved

Phase 4

13292-46-1

5381226 5458213

Pyrazinamide

Approved, Investigational

Phase 4

98-96-4

1046

Isoniazid

Approved, Investigational

Phase 4

54-85-3

3767

Acarbose

Approved, Investigational

Phase 4

56180-94-0

441184

Acetylcarnitine

Approved, Investigational

Phase 4

3040-38-8

7045767

Nitazoxanide

Approved, Investigational, Vet_approved

Phase 4

55981-09-4

41684

Methadone

Approved

Phase 4

76-99-3

4095

Milk thistle

Approved, Experimental, Investigational

Phase 4

65666-07-1

Nelfinavir

Approved

Phase 4

159989-64-7

64143

Zidovudine

Approved

Phase 4

30516-87-1

35370

Everolimus

Approved

Phase 4

159351-69-6

70789204 6442177

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Metformin

Approved

Phase 4

657-24-9

14219 4091

Citalopram

Approved

Phase 4

59729-33-8

2771

Losartan

Approved

Phase 4

114798-26-4

3961

Cobicistat

Approved

Phase 4

1004316-88-4

Hyaluronic acid

Approved, Vet_approved

Phase 4

9004-61-9

53477741

Simethicone

Approved

Phase 4

8050-81-5

chloroquine

Approved, Investigational, Vet_approved

Phase 4

54-05-7

2719

Iron

Approved, Experimental

Phase 4

15438-31-0, 7439-89-6

27284 23925

Colchicine

Approved

Phase 4

64-86-8

2833 6167

Adalimumab

Approved

Phase 4

331731-18-1

16219006

Etanercept

Approved, Investigational

Phase 4

185243-69-0

Sirolimus

Approved, Investigational

Phase 4

53123-88-9

5284616 6436030 46835353

Sargramostim

Approved, Investigational

Phase 4

83869-56-1, 123774-72-1

Lenograstim

Approved, Investigational

Phase 4

135968-09-1

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4

52485-79-7

40400 644073

Efavirenz

Approved, Investigational

Phase 4

154598-52-4

64139

Nevirapine

Approved

Phase 4

129618-40-2

4463

Naloxone

Approved, Vet_approved

Phase 4

465-65-6

5284596

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

6741

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

5755

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Mycophenolic acid

Approved

Phase 4

24280-93-1

446541

Interferon alfacon-1

Approved, Investigational

Phase 4

118390-30-0

9554198

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

tannic acid

Approved

Phase 4

1401-55-4

Benzocaine

Approved, Investigational

Phase 4

94-09-7, 1994-09-7

2337

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Rosiglitazone

Approved, Investigational

Phase 4

122320-73-4

77999

Methylcobalamin

Approved, Investigational

Phase 4

13422-55-4

Interventional clinical trials:

(show top 50) (show all 2615)

#	Name	Status	NCT ID	Phase	Drugs
1	Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment	Unknown status	NCT01724723	Phase 4	entecavir (BARACLUDE®)
2	Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines	Unknown status	NCT03231605	Phase 4
3	A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20)	Unknown status	NCT00216229	Phase 4
4	Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time	Unknown status	NCT01926860	Phase 4
5	Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients	Unknown status	NCT02588937	Phase 4	EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
6	Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study	Unknown status	NCT02639585	Phase 4	Daclinza and Sunvepra
7	Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders	Unknown status	NCT01451801	Phase 4
8	Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults.	Unknown status	NCT02822547	Phase 4	Peginterferon alfa-2a
9	PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab	Unknown status	NCT02523547	Phase 4	Cavir;Baraclude
10	A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study	Unknown status	NCT01829685	Phase 4	Entecavir, Adefovir
11	Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study)	Unknown status	NCT02826070	Phase 4	Telbivudine;Adefovir dipivoxil
12	Investigator Initiated Study of Thymosin in HBV-related HCC	Unknown status	NCT02281266	Phase 4	thymalfasin;nucleoside analog (suggest to use entecavir)
13	Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients	Unknown status	NCT02327702	Phase 4	Emtricitabine
14	Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis	Unknown status	NCT01998620	Phase 4	Ademetionine 2;Ademetionine 1;Ademetionine 3
15	Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis	Unknown status	NCT02024295	Phase 4	Ademethionine;Polyene Phosphatidyl choline;Ademethionine
16	Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy	Unknown status	NCT02482272	Phase 4	Lamivudine;Adefovir;Entecavir
17	A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy	Unknown status	NCT01341743	Phase 4	Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
18	Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma	Unknown status	NCT00768157	Phase 4	antiviral treatment (lamivudine or entecavir)
19	Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B	Unknown status	NCT01380951	Phase 4	telbivudine
20	Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine	Unknown status	NCT01548326	Phase 4	Atorvastatin;placebo
21	A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin	Unknown status	NCT01439776	Phase 4
22	A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients	Unknown status	NCT01436539	Phase 4	Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
23	Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.	Unknown status	NCT02108301	Phase 4	tacrolimus-cyclosporine A
24	Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients	Unknown status	NCT02327676	Phase 4	Emtricitabine
25	Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users: a Randomized, Controlled Trial	Unknown status	NCT02959775	Phase 4
26	Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant	Unknown status	NCT03359746	Phase 4	Grazoprevir/Elbasvir
27	A Randomised, Open-label Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Naive Autoimmune Hepatitis	Unknown status	NCT02900443	Phase 4	Mycophenolate mofetil;Azathioprine
28	The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial	Unknown status	NCT02412319	Phase 4	Anti-HBV placenta transfer factor injection
29	Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin	Unknown status	NCT00575627	Phase 4	Peg-Interferon alpha2a plus Ribavirin
30	Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months	Unknown status	NCT01028326	Phase 4
31	Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma	Unknown status	NCT01765231	Phase 4	Entecavir prophylaxis;Observation arm
32	Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B	Unknown status	NCT02532413	Phase 4	Poly IC;Entecavir
33	A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection	Unknown status	NCT00939068	Phase 4	Telbivudine
34	A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B:	Unknown status	NCT01456312	Phase 4	Peginterferon alfa-2a;Entecavir
35	Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial	Unknown status	NCT00663182	Phase 4	Entecavir
36	A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.	Unknown status	NCT02150291	Phase 4	Neurobion;placebo
37	A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml.	Unknown status	NCT02894918	Phase 4	Peginterferon alfa-2a
38	Emtricitabine for Naive Chinese Chronic Hepatitis B Patients	Unknown status	NCT02327663	Phase 4	Emtricitabine
39	Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients	Unknown status	NCT03332329	Phase 4	Entecavir;Granulocyte Macrophage Colony Stimulating Factor;Y peginterferon alfa-2b;HBV vaccine
40	Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor	Unknown status	NCT02973646	Phase 4	Entecavir or Tenofovir;Peginterferon Alfa-2B
41	Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Hemodialysis Patients in China: a Multicenter Randomized Controlled Trial	Unknown status	NCT02963714	Phase 4
42	Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF	Unknown status	NCT02957994	Phase 4	Tenofovir alafenamide fumarate
43	Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care	Unknown status	NCT03364725	Phase 4	Glecaprevir-pibrentasvir
44	Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in HIV-infected Adults in China	Unknown status	NCT03316807	Phase 4
45	A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy	Unknown status	NCT02594293	Phase 4	PegIFN alfa-2a
46	Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues	Unknown status	NCT01911156	Phase 4	Continue NA treatment;Discontinue NA Treatment
47	Immunologic Response of Hepatitis B Single Dose Versus 3-dose Series in Previously Vaccinated HIV-infected Adults at Maharaj Nakorn Chiang Mai Hospital: A Randomized Controlled Trial	Unknown status	NCT03219203	Phase 4
48	Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment	Unknown status	NCT02365402	Phase 4	Entecavir
49	Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood	Unknown status	NCT01341275	Phase 4
50	The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma	Unknown status	NCT00834860	Phase 4	peginterferon alpha-2a and ribavirin

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Sources

Genetic Tests for Hepatitis a

Sources

Anatomical Context for Hepatitis a

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

¹⁹

Liver

MalaCards organs/tissues related to Hepatitis a:

⁴⁰

Liver, Testes, Kidney, T Cells, Bone, Lung, Skin

Sources

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 12176)

#	Title	Authors	PMID	Year
1	Seroepidemiology of hepatitis viruses, measles, mumps, rubella and varicella among healthcare workers and students: Should we screen before vaccination? ⁴² ⁶¹	Karadeniz A...Akduman Alasehir E	32113699	2020
2	Status of adult immunity to hepatitis A virus in healthcare workers from a tertiary care hospital in north India. ⁴² ⁶¹	Chauhan S...Himanshu D	31939396	2019
3	Booster immunity - diagnosis of chronic hepatitis B viral infection. ⁴² ⁶¹	Komitova RT...Golkocheva-Markova E	32040457	2019
4	Exosomes cloak the virion to transmit Enterovirus 71 non-lytically. ⁶¹	Gu J...Mao L	31885311	2020
5	HAV detection from milk-based products containing soft fruits: Comparison between four different extraction methods. ⁶¹	Battistini R...Serracca L	32454367	2020
6	Heat sensitization of hepatitis A virus and Tulane virus using grape seed extract, gingerol and curcumin. ⁶¹	Patwardhan M...D'Souza DH	32336357	2020
7	Early SARS-CoV-2 outbreak detection by sewage-based epidemiology. ⁶¹	Orive G...Barcelo D	32417555	2020
8	Hepatitis A takes hold in the community. ⁶¹	Heavey E	32558785	2020
9	Hepatitis A takes hold in the community. ⁶¹		32558786	2020
10	Effect of duck hepatitis A virus genotype 3 infection on glucose metabolism of Pekin ducklings and underlying mechanism. ⁶¹	Liang S...Zhang D	32339622	2020
11	Public Health Role of Academic Medical Center in Community Outbreak of Hepatitis A, San Diego County, California, USA, 2016-2018. ⁶¹	Kang M...Torriani FJ	32568038	2020
12	Architect i2000 SR has improved turnaround time for infectious disease serology testing over Vitros ECiQ. ⁶¹	Cheng C...Tang YW	32340767	2020
13	Immunity to hepatitis A among men who have sex with men attending a large sexual health clinic in Melbourne, Australia, 2012-2018. ⁶¹	Vodstrcil LA...Chow EPF	32169881	2020
14	Estimated Additional Number of Adults in HIV Care Who have an Indication for Hepatitis A Vaccination Following 2020 US Guideline Update. ⁶¹	Weiser JK...Shouse RL	32568767	2020
15	Global Epidemiology of Viral Hepatitis. ⁶¹	Razavi H	32389357	2020
16	Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. ⁶¹	Versfeld A...Spearman CW	32522210	2020
17	Homelessness and Hepatitis A-San Diego County, 2016-2018. ⁶¹	Peak CM...McDonald EC	31412358	2020
18	Hepatitis A: Epidemiology, Natural History, Unusual Clinical Manifestations, and Prevention. ⁶¹	Abutaleb A...Kottilil S	32389358	2020
19	Missed Opportunities for Hepatitis A Vaccination Among MSM Initiating PrEP. ⁶¹	Cohall A...Carnevale C	31720939	2020
20	Human Gene Sequences in SARS-CoV-2 and Other Viruses. ⁶¹	Lehrer S...Rheinstein PH	32503822	2020
21	Ongoing transmission of Entamoeba histolytica among newly diagnosed people living with HIV in Taiwan, 2009-2018. ⁶¹	Huang SH...Taiwan HIV Study Group	32530918	2020
22	Can economic indicators predict infectious disease spread? A cross-country panel analysis of 13 European countries. ⁶¹	Hunter PR...Semenza JC	31291826	2020
23	Vaccination coverage rates of military personnel worldwide: a systematic review of the literature. ⁶¹	Arnold JN...Sammito S	32561973	2020
24	Factors associated with anti-hepatitis A virus immunoglobulin G seropositivity among Korean workers: a cross-sectional study. ⁶¹	Mun E...Lee C	32513893	2020
25	Hepatitis A Outbreak with the Concurrence of Salmonella Typhi and Salmonella Poona Infection in Children of Urban Vellore, South India. ⁶¹	Srinivasan M...John J	32228778	2020
26	Factors associated with hepatitis A virus infection among HIV-positive patients before and after implementation of a hepatitis A virus vaccination program at a medical centre in central Taiwan. ⁶¹	Lin JJ...Yang HJ	32571474	2020
27	Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice. ⁶¹	AbdelAllah NH...AbdelGhani S	32114177	2020
28	Acute liver failure in a Mexican family infected with hepatitis A virus. ⁶¹	Garcia-Juarez I...Ville R	31526632	2020
29	First evidence for continuous circulation of hepatitis A virus subgenotype IIA in Central Africa. ⁶¹	Abe H...Yasuda J	32564517	2020
30	Exosome mimicry by a HAVCR1-NPC1 pathway of endosomal fusion mediates hepatitis A virus infection. ⁶¹	Costafreda MI...Kaplan G	32541946	2020
31	Immunogenicity of the hepatitis A vaccine 20 years after infant immunization. ⁶¹	Mosites E...McMahon B	32535018	2020
32	Sexual behaviour and poor hygiene are related to recent hepatitis a virus community outbreaks. ⁶¹	Hernandez Bustabad A...Hernandez-Guerra M	32450702	2020
33	Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients. ⁶¹	Adati EM...Machado CM	32034983	2020
34	Development of a live attenuated duck hepatitis A virus type 3 vaccine (strain SD70). ⁶¹	Wu F...Zhang X	32446833	2020
35	Liver transplant for alcoholic hepatitis: a current clinical overview. ⁶¹	Marot A...Deltenre P	32511039	2020
36	Application of median lethal concentration (LC50) of pathogenic microorganisms and their antigens in vaccine development. ⁶¹	Saganuwan SA	32539814	2020
37	Human genetic basis of fulminant viral hepatitis. ⁶¹	Jouanguy E	32285199	2020
38	Reactive Polymer Targeting dsRNA as Universal Virus Detection Platform with Enhanced Sensitivity. ⁶¹	Ku J...Li S	32233463	2020
39	Identification and genome characterization of a novel picornavirus from ducks in China. ⁶¹	Li Y...Song M	32524264	2020
40	Prevalence of Hepatitis B Virus Infection Among US Adults Aged 20-59 Years With a History of Injection Drug Use: National Health and Nutrition Examination Survey, 2001-2016. ⁶¹	Shing JZ...Jiles RB	31350875	2020
41	Functions of human liver CD69+CD103-CD8+ T cells depend on HIF-2α activity in healthy and pathologic livers. ⁶¹	Kim JH...Shin EC	31987989	2020
42	Development and evaluation of an indirect ELISA based on recombinant structural protein VP2 to detect antibodies against duck hepatitis A virus. ⁶¹	Lai Y...Chen X	32485472	2020
43	Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: A randomized study. ⁶¹	Nakasone M...Carneiro JDA	32376110	2020
44	Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects. ⁶¹	Kankam M...Vilardell D	32301062	2020
45	Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children. ⁶¹	Mutsaerts EAML...Madhi SA	32307279	2020
46	Inactivation by osmotic dehydration and air drying of Salmonella, Shiga toxin-producing Escherichia coli, Listeria monocytogenes, hepatitis A virus and selected surrogates on blueberries. ⁶¹	Bai X...Zuber S	31962220	2020
47	Prolonged cholestasis after acute viral hepatitis: successfully treated with oral steroid. ⁶¹	Jayappa M...Goyal JP	32444440	2020
48	High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer. ⁶¹	Kitsou M...Zaravinos A	32468013	2020
49	Strategies for hepatitis B booster vaccination among children: an 8-year prospective cohort study. ⁶¹	Qiu Y...Li LJ	32429793	2020
50	Assessment of ISO Method 15216 to Quantify Hepatitis E Virus in Bottled Water. ⁶¹	Cuevas-Ferrando E...Randazzo W	32414206	2020

Sources

Genes for Hepatitis a

Genes related to Hepatitis a (0 elite genes):

(show all 28)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	HAVCR1	Hepatitis A Virus Cellular Receptor 1	Protein Coding	48.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Summaries Proteins Functions (show sections)
2	HAVCR2	Hepatitis A Virus Cellular Receptor 2	Protein Coding	29.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Proteins (show sections)
3	TICAM1	Toll Like Receptor Adaptor Molecule 1	Protein Coding	18.34	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Proteins (show sections)
4	IKBKG	Inhibitor Of Nuclear Factor Kappa B Kinase Regulatory Subunit Gamma	Protein Coding	17.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Proteins (show sections)
5	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	16.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	GYPA	Glycophorin A (MNS Blood Group)	Protein Coding	16.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Functions (show sections)
7	ALB	Albumin	Protein Coding	15.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	F2	Coagulation Factor II, Thrombin	Protein Coding	15.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	AFP	Alpha Fetoprotein	Protein Coding	14.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	IFNA1	Interferon Alpha 1	Protein Coding	14.4	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	TNF	Tumor Necrosis Factor	Protein Coding	14.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	GGT1	Gamma-Glutamyltransferase 1	Protein Coding	14.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	SEPSECS	Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase	Protein Coding	13.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	IFNG	Interferon Gamma	Protein Coding	13.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	MAVS	Mitochondrial Antiviral Signaling Protein	Protein Coding	13.34	DISEASES inferred ¹⁵ GeneCards inferred via : Proteins (show sections)
16	IL10	Interleukin 10	Protein Coding	13.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	13.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	TLR3	Toll Like Receptor 3	Protein Coding	13.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	TLR4	Toll Like Receptor 4	Protein Coding	13.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	INS	Insulin	Protein Coding	12.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	F3	Coagulation Factor III, Tissue Factor	Protein Coding	12.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	12.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	IFNA2	Interferon Alpha 2	Protein Coding	12.81	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	IL4	Interleukin 4	Protein Coding	12.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	ASGR1	Asialoglycoprotein Receptor 1	Protein Coding	12.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
26	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	12.47	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
27	IL1B	Interleukin 1 Beta	Protein Coding	12.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
28	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	12.27	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Hepatitis a

Sources

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Sources

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 45)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	14.03	TNF TLR4 TLR3 TICAM1 MAVS INS
2	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.96	TNF TLR4 TLR3 TICAM1 INS IKBKG
3	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	12.93	TNF TLR4 TLR3 TICAM1 IKBKG IFNA1
4	Allograft rejection ¹ ³⁶ Show member pathways Antigen processing and presentation ³⁶ Asthma ³⁶ Autoimmune thyroid disease ³⁶ CTL Mediated Apoptosis ⁶³ Graft-versus-host disease ³⁶ Intestinal immune network for IgA production ³⁶ THC Differentiation Pathway ⁶³ Type I diabetes mellitus ³⁶ Viral myocarditis ³⁶	12.83	TNF INS IL10 IFNG IFNA1
5	Herpes simplex virus 1 infection ³⁶	12.76	TNF TLR3 TICAM1 MAVS IKBKG IFNG
6	Toll-Like receptor Signaling Pathways ⁶⁴ Show member pathways IL-1 Family Signaling Pathways ⁶⁴ Immune response IL-1 signaling pathway ²² Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Inflammasome Activation Pathways ⁶⁴ Mucin expression in CF via TLRs, EGFR signaling pathways ²² NOD-like Receptor Signaling Pathways ⁶⁴	12.7	TNF TLR4 TLR3 TICAM1 IKBKG IFNA1
7	Toll-like Receptor Signaling Pathway ³⁶ ¹ Show member pathways Chagas disease (American trypanosomiasis) ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ Regulation of toll-like receptor signaling pathway ¹	12.7	TNF TLR4 TLR3 TICAM1 MAVS IL10
8	Th17 cell differentiation ³⁶ Show member pathways IL-22 Pathway ⁶³ Immune response IL-22 signaling pathway ²² Inflammatory bowel disease (IBD) ³⁶ Th1 and Th2 cell differentiation ³⁶	12.59	TNF TLR4 IL10 IKBKG IFNG
9	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.58	TNF IL10 IKBKG IFNG F2
10	Measles ³⁶ Show member pathways Epstein-Barr virus infection ³⁶ Influenza A ³⁶	12.57	TNF TLR4 TLR3 TICAM1 MAVS IKBKG
11	T cell receptor signaling pathway ³⁶ Show member pathways PD-L1 expression and PD-1 checkpoint pathway in cancer ³⁶ T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.56	TNF TLR4 TICAM1 IL10 IKBKG IFNG
12	Cytosolic sensors of pathogen-associated DNA ⁶⁵ Show member pathways Cytosolic DNA-sensing pathway ³⁶ DEx/H-box helicases activate type I IFN and inflammatory cytokines production ⁶⁵ IkBA variant leads to EDA-ID ⁶⁵ IKBKB deficiency causes SCID ⁶⁵ IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) ⁶⁵ IRF3 mediated activation of type 1 IFN ⁶⁵ IRF3-mediated induction of type I IFN ⁶⁵ LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production ⁶⁵ Regulation by TREX1 ⁶⁵ Regulation of innate immune responses to cytosolic DNA ⁶⁵ RIP-mediated NFkB activation via ZBP1 ⁶⁵ STAT6-mediated induction of chemokines ⁶⁵ STING mediated induction of host immune responses ⁶⁵ TAK1 activates NFkB by phosphorylation and activation of IKKs complex ⁶⁵ TRAF6 mediated NF-kB activation ⁶⁵ ZBP1(DAI) mediated induction of type I IFNs ⁶⁵	12.55	TLR3 TICAM1 MAVS IKBKG IFNA1
13	RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways ⁶⁵ Show member pathways Negative regulators of RIG-I/MDA5 signaling ⁶⁵ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁵ RIG-I-like Receptor Signaling ¹ RIG-I-like receptor signaling pathway ³⁶ TRAF3-dependent IRF activation pathway ⁶⁵ TRAF6 mediated IRF7 activation ⁶⁵	12.54	TNF MAVS IKBKG IFNG IFNA1
14	CASP8 activity is inhibited ⁶⁵ Show member pathways Caspase activation via extrinsic apoptotic signalling pathway ⁶⁵ Dimerization of procaspase-8 ⁶⁵ FAS (CD95) signaling pathway ¹ Ligand-dependent caspase activation ⁶⁵ Ligand-independent caspase activation via DCC ⁶⁵ Regulated Necrosis ⁶⁵ Regulation by c-FLIP ⁶⁵ Regulation of necroptotic cell death ⁶⁵ RIPK1-mediated regulated necrosis ⁶⁵ TRAIL signaling ⁶⁵ TRAIL signaling pathway ¹	12.29	TLR4 TLR3 TICAM1 IKBKG
15	Pathogenic Escherichia coli infection ³⁶	12.27	TNF TLR4 IKBKG F2
16	Toll Comparative Pathway ⁶³ Show member pathways IL-1 Pathway ⁶³ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶³ TLR-TRIF Pathway ⁶³	12.27	TNF TLR4 TLR3 TICAM1 IKBKG IFNG
17	Diseases associated with the TLR signaling cascade ⁶⁵ Show member pathways Diseases of Immune System ⁶⁵ Interleukin-1 Induced Activation of NF-kappa-B ¹ IRAK1 recruits IKK complex ⁶⁵ IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation ⁶⁵ IRAK4 deficiency (TLR2/4) ⁶⁵ IRAK4 deficiency (TLR5) ⁶⁵ MyD88 deficiency (TLR2/4) ⁶⁵ MyD88 deficiency (TLR5) ⁶⁵ Simplified Depiction of MYD88 Distinct Input-Output Pathway ¹ TLR4 Signaling and Tolerance ¹ Toll-like Receptor Signaling ¹	12.24	TNF TLR4 TLR3 TICAM1 IKBKG
18	Folate Metabolism ¹ Show member pathways Selenium Micronutrient Network ¹ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	12.24	TNF INS IFNG GGT1 F2 ALB
19	Toxoplasmosis ³⁶ Show member pathways Leishmaniasis ³⁶	12.23	TNF TLR4 IL10 IKBKG IFNG
20	Tuberculosis ³⁶	12.2	TNF TLR4 IL10 IFNG IFNA1
21	Colorectal Cancer Metastasis ⁶³	12.19	TNF TLR4 TLR3 IFNG
22	Bacterial infections in CF airways ²² Show member pathways IL-1 beta-dependent CFTR expression ²² Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²²	12.19	TNF TLR4 IKBKG IFNG
23	NOD-like receptor signaling pathway ³⁶	12.14	TNF TLR4 TICAM1 MAVS IKBKG IFNA1
24	Necroptosis ³⁶ Show member pathways Nanoparticle triggered regulated necrosis ¹	12.03	TNF TLR4 TLR3 TICAM1 IFNG IFNA1
25	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁴	11.99	TNF IL10 IFNG GYPA
26	Yersinia infection ³⁶	11.95	TNF TLR4 TICAM1 IL10 IKBKG
27	NF-kappa B signaling pathway ³⁶	11.93	TNF TLR4 TICAM1 IKBKG
28	Amoebiasis ³⁶	11.91	TNF TLR4 IL10 IFNG
29	NF-kB(NFkB) Pathway ⁶⁶	11.9	TNF TLR4 TICAM1 IKBKG
30	IL27-mediated signaling events ¹ Show member pathways IL12 Signaling Pathway ⁶⁶ Th1 Differentiation ⁶⁴	11.88	TNF TLR4 TLR3 IL10 IFNG
31	NF-kappaB Signaling ⁴	11.84	TNF TLR3 TICAM1 MAVS IL10 IKBKG
32	Innate Lymphoid Cells Differentiation ⁶⁴	11.77	TNF IL10 IFNG
33	Pertussis ³⁶	11.76	TNF TLR4 TICAM1 IL10
34	Dendritic Cells Developmental Lineage Pathway ⁶⁴	11.73	TNF IL10 IFNG
35	Transcription_NF-kB signaling pathway ²²	11.59	TNF TLR4 IKBKG
36	Cellular Transformation by HTLV1 ⁶³ Show member pathways Activation of NF-KappaB by PKR ⁶³	11.56	TNF IKBKG IFNG
37	MSP-RON Signaling ⁶³	11.52	TNF TLR4 IFNG
38	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.49	TNF IFNG CYP3A4
39	FOXA2 and FOXA3 transcription factor networks ¹	11.45	INS F2 ALB AFP
40	African trypanosomiasis ³⁶	11.38	TNF IL10 IFNG
41	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁴ Show member pathways IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁴	11.37	TNF IL10 IFNG
42	IL-10 Pathway ⁶³	11.35	TNF TLR4 IL10
43	Cytokines and Inflammatory Response ¹	11.26	TNF IL10 IFNG
44	IKK complex recruitment mediated by RIP1 ⁶⁵	11.05	TLR4 TLR3 TICAM1 IKBKG
45	Malaria ³⁶	11.05	TNF TLR4 IL10 IFNG GYPA

Sources

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.36	TNF TLR3 INS IL10 IFNG IFNA1

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show top 50) (show all 64)

#	Name	GO ID	Score	Top Affiliating Genes
1	innate immune response	GO:0045087	10.18	TLR4 TLR3 TICAM1 MAVS IKBKG HAVCR2
2	positive regulation of gene expression	GO:0010628	10.14	TNF TLR4 TLR3 TICAM1 INS IFNG
3	immune response	GO:0006955	10.13	TNF TLR4 IL10 IKBKG IFNG
4	inflammatory response	GO:0006954	10.09	TNF TLR4 TLR3 TICAM1 IKBKG HAVCR2
5	defense response to bacterium	GO:0042742	10.07	TNF TLR4 TLR3 MAVS IL10
6	cellular protein metabolic process	GO:0044267	10.03	INS F2 ALB AFP
7	positive regulation of protein phosphorylation	GO:0001934	10.02	TNF MAVS IFNG F2
8	defense response to virus	GO:0051607	10.02	TLR3 TICAM1 MAVS IFNG IFNA1
9	response to lipopolysaccharide	GO:0032496	10.01	TLR4 TICAM1 IL10 GGT1
10	cellular response to lipopolysaccharide	GO:0071222	10	TNF TLR4 TICAM1 IL10 HAVCR2
11	response to virus	GO:0009615	9.97	TNF TLR3 IKBKG IFNG
12	positive regulation of inflammatory response	GO:0050729	9.93	TNF TLR4 TLR3 IFNG
13	positive regulation of JNK cascade	GO:0046330	9.91	TNF TLR4 TLR3
14	apoptotic signaling pathway	GO:0097190	9.91	TNF TLR4 TLR3 TICAM1
15	humoral immune response	GO:0006959	9.9	TNF IFNG IFNA1
16	negative regulation of tumor necrosis factor production	GO:0032720	9.89	TLR4 IL10 HAVCR2
17	positive regulation of NIK/NF-kappaB signaling	GO:1901224	9.89	TNF TLR4 TLR3 HAVCR2
18	positive regulation of interferon-gamma production	GO:0032729	9.88	TNF TLR4 HAVCR2
19	extrinsic apoptotic signaling pathway	GO:0097191	9.88	TNF TLR3 IFNG
20	lipopolysaccharide-mediated signaling pathway	GO:0031663	9.88	TNF TLR4 TICAM1
21	positive regulation of interleukin-6 production	GO:0032755	9.87	TNF TLR4 TLR3 TICAM1
22	response to exogenous dsRNA	GO:0043330	9.86	TLR3 TICAM1 IFNA1
23	positive regulation of cytokine production	GO:0001819	9.86	TNF TLR3 HAVCR2
24	positive regulation of JAK-STAT cascade	GO:0046427	9.86	TNF IL10 F2
25	positive regulation of tumor necrosis factor production	GO:0032760	9.86	TLR4 TLR3 TICAM1 MAVS
26	negative regulation of interferon-gamma production	GO:0032689	9.85	TLR4 IL10 HAVCR2
27	microglial cell activation	GO:0001774	9.85	TNF TLR3 IFNG
28	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	9.85	TNF TLR4 TLR3 TICAM1 MAVS IKBKG
29	positive regulation of interferon-beta production	GO:0032728	9.84	TLR4 TLR3 MAVS
30	positive regulation of nitric oxide biosynthetic process	GO:0045429	9.84	TNF TLR4 TICAM1 IFNG
31	positive regulation of interleukin-12 production	GO:0032735	9.82	TLR4 TLR3 IFNG
32	positive regulation of tumor necrosis factor secretion	GO:1904469	9.82	MAVS IFNG HAVCR2
33	positive regulation of cytokine production involved in inflammatory response	GO:1900017	9.81	TNF TLR4 TICAM1
34	positive regulation of interleukin-6 secretion	GO:2000778	9.81	TNF TLR4 MAVS IFNG
35	necroptotic process	GO:0070266	9.8	TLR4 TLR3 TICAM1
36	positive regulation of macrophage activation	GO:0043032	9.8	TLR4 IL10 HAVCR2
37	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.8	TNF TLR4 TLR3 TICAM1 INS IKBKG
38	negative regulation of interleukin-6 production	GO:0032715	9.78	TNF TLR4 IL10 HAVCR2
39	macrophage activation involved in immune response	GO:0002281	9.76	TICAM1 IFNG HAVCR2
40	positive regulation of cytokine secretion	GO:0050715	9.76	TNF INS IL10 IFNG
41	toll-like receptor 3 signaling pathway	GO:0034138	9.75	TLR3 TICAM1 HAVCR2
42	negative regulation of amyloid-beta clearance	GO:1900222	9.73	TNF IFNG
43	positive regulation of interleukin-1 beta biosynthetic process	GO:0050725	9.73	TNF IFNG
44	necroptotic signaling pathway	GO:0097527	9.73	TNF TLR3
45	TRIF-dependent toll-like receptor signaling pathway	GO:0035666	9.73	TLR4 TLR3 TICAM1 IKBKG
46	endothelial cell apoptotic process	GO:0072577	9.72	TNF IL10
47	positive regulation of myeloid dendritic cell cytokine production	GO:0002735	9.72	TICAM1 MAVS
48	positive regulation of MHC class II biosynthetic process	GO:0045348	9.72	TLR4 IL10 IFNG
49	negative regulation of cytokine production involved in immune response	GO:0002719	9.71	TNF IL10
50	negative regulation of cytokine secretion involved in immune response	GO:0002740	9.71	TNF IL10

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine activity	GO:0005125	8.92	TNF IL10 IFNG IFNA1

Sources

Sources for Hepatitis a

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia